<DOC>
	<DOCNO>NCT01357161</DOCNO>
	<brief_summary>This study safety efficacy MK-1775 combination paclitaxel + carboplatin treatment ovarian , fallopian tube , primary peritoneal tumor P53 mutation . In Part 1 , small group participant receive MK-1775 along paclitaxel carboplatin find maximum tolerable MK-1775 dose combination . Pharmacokinetics also assess period . In Part 2 , participant randomly assign receive either MK-1775 + paclitaxel + carboplatin placebo + paclitaxel + carboplatin .</brief_summary>
	<brief_title>A Study MK-1775 Combination With Paclitaxel Carboplatin Versus Paclitaxel Carboplatin Alone Participants With Platinum-Sensitive Ovarian Tumors With P53 Gene Mutation ( MK-1775-004 )</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically confirm nonlow grade , nonborderline ( low malignant potential ) ovarian , fallopian tube , primary peritoneal cancer progress paclitaxel / platinumbased therapy . Platinumsensitive disease . Radiological progression must occur 6 month completion recent platinumbased treatment . Measurable disease . Available tumor sample ( ) . Performance status ≤1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale . Adequate organ function . Pregnancy intention become pregnant course study . Participation study investigational compound device within 28 day receive first dose study medication . Active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Primary CNS tumor . Known hypersensitivity contraindication component potential study therapy ( paclitaxel , carboplatin , MK1775 ) analog ( i.e . cremophor , mannitol , etc. ) . Participant require use medication product metabolize , inhibit , induce Cytochrome P450 3A ( CYP3A4 ) . Ongoing peripheral neuropathy ≥Grade 2 related previous treatment . Known psychiatric substance abuse disorder . Regular use ( include `` recreational use '' ) illicit drug recent history ( within last year ) drug alcohol abuse . HIV positive . Active Hepatitis B C. Symptomatic ascites pleural effusion . Clinical history suggestive Li Fraumeni Syndrome .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>